PE20010685A1 - COMPOSITION INCLUDING AN INTERLEUQUIN 1 RECEPTOR ANTAGONIST POLYPEPTIDE AND A DIARYLSULPHONYLUREA AS AN INHIBITOR OF IL-1 PROCESSING AND RELEASE - Google Patents
COMPOSITION INCLUDING AN INTERLEUQUIN 1 RECEPTOR ANTAGONIST POLYPEPTIDE AND A DIARYLSULPHONYLUREA AS AN INHIBITOR OF IL-1 PROCESSING AND RELEASEInfo
- Publication number
- PE20010685A1 PE20010685A1 PE2000000942A PE0009422000A PE20010685A1 PE 20010685 A1 PE20010685 A1 PE 20010685A1 PE 2000000942 A PE2000000942 A PE 2000000942A PE 0009422000 A PE0009422000 A PE 0009422000A PE 20010685 A1 PE20010685 A1 PE 20010685A1
- Authority
- PE
- Peru
- Prior art keywords
- interleuquin
- release
- processing
- urea
- hydroxy
- Prior art date
Links
- 108010002352 Interleukin-1 Proteins 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- -1 CYANE Chemical class 0.000 abstract 5
- 239000004202 carbamide Substances 0.000 abstract 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 abstract 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A USO DE UNA COMPOSICION QUE COMPRENDE: a)UN POLIPEPTIDO ANTAGONISTA DEL RECEPTOR DE INTERLEUQUINA 1 (IL-1ra), DE PREFERENCIA DE UNA SECUENCIA (ID SEQ N°2) DE 169 AMINOACIDOS; b)UN AGENTE NO ESTEROIDEO QUE INHIBE EL PROCESAMIENTO Y LA LIBERACION DE IL-1 TAL COMO DIARILSULFONILUREA R1-(O=)S(=O)-NH-C(=O)-NH-R2; DONDE R1 Y R2 SON UN GRUPO DE FORMULA II EN LA QUE LAS LINEAS --- REPRESENTAN DOBLES ENLACES OPCIONALES; n ES 0-3; A, B, D, E Y G SON O, S, N, CR5R6; R5 Y R6 SON H, ALQUILO C1-C6, HALOGENO, CIANO, AMINO, OH, ENTRE OTROS, SIENDO COMPUESTOS SELECCIONADOS 1-(1,2,3,5,6,7-HEXAHIDRO-s-INDACEN-4-IL)-3-[4-(1-HIDROXI-1-METIL-ETIL)-FURANO-2-SULFONIL]-UREA, 1-(2,6-DIISOPROPIL-FENIL)-3-[4-(1-HIDROXI-1-METIL-ETIL-FURANO-2-SULFONIL]-UREA, 1-(4-CLORO-2,6-DIISOPROPIL-FENIL)-3-[3-(HIDROXI-1-METIL-ETIL)-BENCENOSULFONIL]-UREA, ENTRE OTROS. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE TRASTORNOS INFLAMATORIOS TAL COMO ARTRITIS REUMATOIDE, OSTEOARTRITIS, ASMA, NEURODEGENERACION, ENTRE OTROSIT REFERS TO THE USE OF A COMPOSITION THAT INCLUDES: a) AN ANTAGONIST POLYPEPTIDE OF THE INTERLEUQUIN 1 RECEPTOR (IL-1ra), OF PREFERENCE OF A SEQUENCE (ID SEQ N ° 2) OF 169 AMINO ACIDS; b) A NON-STEROID AGENT THAT INHIBITS THE PROCESSING AND RELEASE OF IL-1 SUCH AS DIARYLSULFONYLUREA R1- (O =) S (= O) -NH-C (= O) -NH-R2; WHERE R1 AND R2 ARE A GROUP OF FORMULA II IN WHICH THE LINES --- REPRESENT DOUBLE OPTIONAL LINKS; n IS 0-3; A, B, D, E, and G ARE O, S, N, CR5R6; R5 AND R6 ARE H, C1-C6 ALKYL, HALOGEN, CYANE, AMINO, OH, AMONG OTHERS, BEING SELECTED COMPOUNDS 1- (1,2,3,5,6,7-HEXAHIDRO-s-INDACEN-4-IL) -3- [4- (1-HYDROXY-1-METHYL-ETHYL) -FURANO-2-SULFONIL] -UREA, 1- (2,6-DIISOPROPYL-PHENYL) -3- [4- (1-HYDROXY-1 -MEthyl-ETHYL-FURANE-2-SULFONIL] -UREA, 1- (4-CHLORO-2,6-DIISOPROPYL-PHENYL) -3- [3- (HYDROXY-1-METHYL-ETHYL) -BENZENOSULFONIL] -UREA, AMONG OTHERS, THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF INFLAMMATORY DISORDERS SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, ASTHMA, NEURODEGENERATION, AMONG OTHERS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15401099P | 1999-09-14 | 1999-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010685A1 true PE20010685A1 (en) | 2001-07-03 |
Family
ID=22549650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000942A PE20010685A1 (en) | 1999-09-14 | 2000-09-12 | COMPOSITION INCLUDING AN INTERLEUQUIN 1 RECEPTOR ANTAGONIST POLYPEPTIDE AND A DIARYLSULPHONYLUREA AS AN INHIBITOR OF IL-1 PROCESSING AND RELEASE |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1214087A1 (en) |
| JP (1) | JP2003509378A (en) |
| AR (1) | AR033650A1 (en) |
| AU (1) | AU6464400A (en) |
| BR (1) | BR0014003A (en) |
| CA (1) | CA2383026A1 (en) |
| CO (1) | CO5190701A1 (en) |
| EC (1) | ECSP003652A (en) |
| GT (1) | GT200000155A (en) |
| PA (1) | PA8502901A1 (en) |
| PE (1) | PE20010685A1 (en) |
| TN (1) | TNSN00183A1 (en) |
| WO (1) | WO2001019390A1 (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57852B1 (en) | 2004-04-02 | 2018-12-31 | Swedish Orphan Biovitrum Ab Publ | Methods of reducing aggregation of il-1ra |
| WO2008129288A2 (en) * | 2007-04-19 | 2008-10-30 | Boehringer Ingelheim International Gmbh | Disulfonamides useful in the treatment of inflammation |
| PT3259253T (en) * | 2015-02-16 | 2020-03-11 | Univ Queensland | SULPHONYLURE AND RELATED COMPOUNDS AND USE OF THE SAME |
| HK1257569A1 (en) | 2016-02-16 | 2019-10-25 | The University Of Queensland | Sulfonylureas and related compounds and use of same |
| MA56008A (en) * | 2016-04-18 | 2022-04-06 | Novartis Ag | COMPOUNDS AND COMPOSITIONS FOR DEALING WITH STATES ASSOCIATED WITH NLRP ACTIVITY |
| MX2019008592A (en) | 2017-01-23 | 2019-11-21 | Genentech Inc | Chemical compounds as inhibitors of interleukin-1 activity. |
| CA3059458A1 (en) | 2017-05-24 | 2018-11-29 | The University Of Queensland | Novel compounds and uses |
| EP3634951B8 (en) | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| WO2019008029A1 (en) | 2017-07-07 | 2019-01-10 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| JP7235742B2 (en) | 2017-07-07 | 2023-03-08 | インフレイゾーム リミテッド | Novel sulfonamide carboxamide compound |
| CN111094243B (en) | 2017-07-24 | 2023-09-05 | 诺华股份有限公司 | Compounds and compositions for treating conditions associated with NLRP activity |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| RU2020110219A (en) * | 2017-08-15 | 2021-09-17 | Инфлазоум Лимитед | SULFONYLUREAS AND SULFONYLTHIUREAS AS NLRP3 INHIBITORS |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| US11518739B2 (en) | 2017-08-15 | 2022-12-06 | Inflazome Limited | Sulfonamide carboxamide compounds |
| CA3071145A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | Novel substituted sulfonylurea derivatives |
| EP3692020A1 (en) | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
| RU2020115098A (en) | 2017-11-09 | 2021-12-10 | Инфлазоум Лимитед | COMPOUNDS OF NEW SULFONAMIDE CARBOXAMIDES |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019166627A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| EP3759090A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| US12168653B2 (en) | 2018-03-02 | 2024-12-17 | Inflazome Limited | Sulfonamide derivates as NLRP3 inhibitors |
| WO2019166632A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| US11884645B2 (en) | 2018-03-02 | 2024-01-30 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| GB201806578D0 (en) * | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| EP3817817A1 (en) | 2018-07-03 | 2021-05-12 | Novartis AG | Nlrp modulators |
| JP7411631B2 (en) | 2018-07-20 | 2024-01-11 | エフ． ホフマン－ラ ロシュ アーゲー | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| WO2020018975A1 (en) | 2018-07-20 | 2020-01-23 | Genentech, Inc. | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CA3108948A1 (en) | 2018-08-15 | 2020-02-20 | Inflazome Limited | Novel sulfonamideurea compounds |
| EP3870565A1 (en) * | 2018-10-24 | 2021-09-01 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| CA3126467A1 (en) | 2019-01-14 | 2020-07-23 | Cadila Healthcare Limited | Novel substituted sulfonylurea derivatives |
| CN111875694B (en) * | 2020-05-25 | 2022-07-05 | 北京伟德杰生物科技有限公司 | Interleukin-1 receptor antagonist and fusion protein containing same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874424A (en) * | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| DE69729762T2 (en) * | 1997-01-29 | 2005-07-14 | Pfizer Inc. | 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonylurea derivatives |
| US6015790A (en) * | 1997-10-06 | 2000-01-18 | Basf Aktiengesellschaft | Methods and compositions for treating rheumatoid arthritis |
| EP0987552A3 (en) * | 1998-08-31 | 2000-06-07 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
-
2000
- 2000-08-28 AU AU64644/00A patent/AU6464400A/en not_active Abandoned
- 2000-08-28 EP EP00951799A patent/EP1214087A1/en not_active Withdrawn
- 2000-08-28 WO PCT/IB2000/001192 patent/WO2001019390A1/en not_active Ceased
- 2000-08-28 CA CA002383026A patent/CA2383026A1/en not_active Abandoned
- 2000-08-28 BR BR0014003-1A patent/BR0014003A/en not_active IP Right Cessation
- 2000-08-28 JP JP2001523022A patent/JP2003509378A/en active Pending
- 2000-09-05 CO CO00066883A patent/CO5190701A1/en not_active Application Discontinuation
- 2000-09-11 PA PA20008502901A patent/PA8502901A1/en unknown
- 2000-09-12 AR ARP000104779A patent/AR033650A1/en not_active Application Discontinuation
- 2000-09-12 PE PE2000000942A patent/PE20010685A1/en not_active Application Discontinuation
- 2000-09-12 EC EC2000003652A patent/ECSP003652A/en unknown
- 2000-09-13 TN TNTNSN00183A patent/TNSN00183A1/en unknown
- 2000-09-14 GT GT200000155A patent/GT200000155A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0014003A (en) | 2002-05-21 |
| CO5190701A1 (en) | 2002-08-29 |
| CA2383026A1 (en) | 2001-03-22 |
| TNSN00183A1 (en) | 2005-11-10 |
| EP1214087A1 (en) | 2002-06-19 |
| GT200000155A (en) | 2002-03-08 |
| ECSP003652A (en) | 2002-04-23 |
| PA8502901A1 (en) | 2002-02-21 |
| AU6464400A (en) | 2001-04-17 |
| WO2001019390A1 (en) | 2001-03-22 |
| AR033650A1 (en) | 2004-01-07 |
| JP2003509378A (en) | 2003-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010685A1 (en) | COMPOSITION INCLUDING AN INTERLEUQUIN 1 RECEPTOR ANTAGONIST POLYPEPTIDE AND A DIARYLSULPHONYLUREA AS AN INHIBITOR OF IL-1 PROCESSING AND RELEASE | |
| PE20040840A1 (en) | 4-OXOQUINOLINE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE | |
| AR038563A1 (en) | ZIPRASIDONE COMPOSITION AND SYNTHETIC CONTROLS | |
| ATE420644T1 (en) | CONDENSED AZABICYCLIC COMPOUNDS AS INHIBITORS OF THE VANILLOID RECEPTOR 1 (VR1) | |
| DE602004012858D1 (en) | 2-AMINOBENZOTHIAZOLE AS CB1 RECEPTOR INVERSE AGONISTS | |
| MX2007013065A (en) | Dihydrobenzofuran derivatives and uses thereof. | |
| ATE290059T1 (en) | SURFACTANT COMPOSITION CONTAINING GEMINITENSIDE AND CO-AMPHIPHILS, THEIR PREPARATION AND THEIR USE | |
| BR0007595A (en) | 4- (heterocyclisulfonamido) -5-methoxy-6- (2-methoxyphenoxide) -2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists | |
| NO20063470L (en) | Tetrazole compounds and their use of metabotrophic glutamate receptor antagonists | |
| BRPI0413305A (en) | fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 receptor (vr1) | |
| AR028824A1 (en) | NPY-5 ANTAGONIST COMPOUNDS AND ITS USE IN THE MANUFACTURE OF MEDICINES. | |
| DE602005020655D1 (en) | Carboxamide-spirolactam CGRP Receptor Antagonists | |
| BR0315644A (en) | Piperazinyl and diazapanyl benzamides and benzothioamides | |
| UY28150A1 (en) | THERAPEUTIC AGENTS | |
| DE602006007556D1 (en) | HETEROARYLSULFONYL STILENE AS 5-HT2A ANTAGONISTS | |
| PE20060298A1 (en) | BENZHIMIDAZOLONE CARBOXYL ACID DERIVATIVES | |
| PE20030872A1 (en) | PHARMACEUTICAL COMPOSITION OF THE 5HT4 TEGASEROD PARTIAL AGONIST | |
| SE0403171D0 (en) | New compounds | |
| ATE374190T1 (en) | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | |
| PE16299A1 (en) | 2-IMIDAZOLINYLAMINOINDOL COMPOUNDS USEFUL AS ALPHA-2 ADRENORECEPTOR AGONISTS | |
| PE83999A1 (en) | AZETIDINS | |
| PL374019A1 (en) | Benzoxazine derivatives as 5-ht6 modulators and uses thereof | |
| BR0211761A (en) | depsipeptides and processes for preparing them | |
| PE20030974A1 (en) | CORTICOTROPIN RELEASING FACTOR RECEPTOR 2 AGONISTS | |
| UY27232A1 (en) | NEW SUBSTITUTED CYAN DIHYDROPIRIMIDINE COMPOUNDS AND THEIR USE FOR TREATMENT OF MATTERS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |